|Bid||20.00 x 0|
|Ask||21.50 x 0|
|Day's range||20.00 - 21.50|
|52-week range||20.00 - 40.50|
|Beta (5Y monthly)||1.60|
|PE ratio (TTM)||N/A|
|Earnings date||03 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The big shareholder groups in Allergy Therapeutics plc ( LON:AGY ) have power over the company. Institutions often own...
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two pivotal trials Portfolio focused on high value growth products to enhance future profitabilityGround-breaking Phase I trial of peanut allergy vaccine on track to commence in 2022 following recent FDA clearance of IND application with data expected sooner than previously anticipatedPivotal Phase III trial of short-cou
It hasn't been the best quarter for Allergy Therapeutics plc ( LON:AGY ) shareholders, since the share price has fallen...